Gemina Laboratories Ltd. (GLABF)
USD 0.44
(-2.91%)
USD 0.44
(-2.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 284.33 Thousand CAD | 207.03% |
| 2023 | 157.74 Thousand CAD | 114.21% |
| 2022 | -1.11 Million CAD | -41.65% |
| 2021 | -783.82 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | 284.33 Thousand CAD | -43.18% |
| 2024 FY | 284.33 Thousand CAD | 80.25% |
| 2024 Q2 | 206.25 Thousand CAD | 124.8% |
| 2024 Q3 | 500.39 Thousand CAD | 142.61% |
| 2024 Q1 | -831.53 Thousand CAD | -627.13% |
| 2023 Q3 | -334.07 Thousand CAD | 88.64% |
| 2023 Q2 | -2.94 Million CAD | -978.11% |
| 2023 Q1 | -272.75 Thousand CAD | 75.43% |
| 2023 FY | 157.74 Thousand CAD | 114.21% |
| 2023 Q4 | 157.74 Thousand CAD | 147.22% |
| 2022 Q2 | -1.36 Million CAD | 34.63% |
| 2022 Q1 | -2.08 Million CAD | -147.25% |
| 2022 FY | -1.11 Million CAD | -41.65% |
| 2022 Q4 | -1.11 Million CAD | 48.31% |
| 2022 Q3 | -2.14 Million CAD | -57.41% |
| 2021 Q4 | -844.34 Thousand CAD | 0.0% |
| 2021 FY | -783.82 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 98.196% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 93.095% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.785% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.336% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 104.51% |
| Mesoblast Limited | 55.85 Million USD | 99.491% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 69.333% |
| Genus plc | 190.6 Million USD | 99.851% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 87.283% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 76.576% |
| Marizyme, Inc. | 18.56 Million USD | 98.469% |
| ContraFect Corporation | -6.02 Million USD | 104.718% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 58.186% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -111.184% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 75.391% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 87.319% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 94.832% |
| MultiCell Technologies, Inc. | 90.04 USD | -315688.538% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 138.739% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 97.804% |
| EV Biologics, Inc. | 1.36 Million USD | 79.215% |
| Q BioMed Inc. | 4.06 Million USD | 92.997% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.069% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 54.314% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 71.784% |
| Biomind Labs Inc. | 711.4 Thousand USD | 60.032% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 99.741% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 97.78% |
| Skye Bioscience, Inc. | -5.72 Million USD | 104.97% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 66.947% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -103.382% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 94.966% |
| IMV Inc. | 7.67 Million USD | 96.293% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -1331.197% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 87.087% |
| GB Sciences, Inc. | 1.74 Million USD | 83.727% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 254.709% |
| HST Global, Inc. | 96.79 Thousand USD | -193.757% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Halberd Corporation | 144.72 Thousand USD | -96.472% |
| Enzolytics Inc. | 981.65 Thousand USD | 71.035% |
| Resverlogix Corp. | 6.45 Million USD | 95.592% |
| Affymax, Inc. | -5.59 Million USD | 105.08% |
| SYBLEU INC | 473.71 Thousand USD | 39.977% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 142.243% |
| argenx SE | -2.02 Billion USD | 100.014% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.345% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.605% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 89.503% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 103.217% |
| AVAX Technologies, Inc. | -5.9 Million USD | 104.817% |
| Zenith Capital Corp. | 10.06 Thousand USD | -2725.278% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.027% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -41.862% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 88.083% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -72.839% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.53% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 85.779% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 111.064% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 20.954% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 98.598% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 1652.222% |
| BioStem Technologies, Inc. | 4.47 Million USD | 93.642% |
| ONE Bio Corp. | 9.04 Million USD | 96.855% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -41.282% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 21805.038% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -37.882% |
| Agentix Corp. | 37.63 Thousand USD | -655.59% |
| LadRx Corporation | -2.03 Million USD | 113.962% |
| Cell Source, Inc. | 9.23 Million USD | 96.92% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 1493.258% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 55.234% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 55.234% |
| NovAccess Global Inc. | 2.17 Million USD | 86.948% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 95.979% |
| Itoco Inc. | 228.3 Thousand USD | -24.542% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -109.087% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 94.264% |
| Kadimastem Ltd | -253.1 Thousand USD | 212.34% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 29.243% |
| CytoDyn Inc. | 20.26 Million USD | 98.597% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 44046.832% |
| Mobile Lads Corp. | 484.23 Thousand USD | 41.281% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 3167.82% |
| Qrons Inc. | 351.42 Thousand USD | 19.091% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 96.31% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 213.908% |
| Rebus Holdings, Inc. | 305 Thousand USD | 6.775% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 93.62% |
| International Stem Cell Corporation | 2.59 Million USD | 89.022% |
| Bioxytran, Inc. | 1.89 Million USD | 85.026% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -355.572% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 86.962% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 91.72% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 96.676% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 63.198% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 122.747% |
| Neutra Corp. | 52.18 Thousand USD | -444.841% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 111.424% |
| PureTech Health plc | -167.19 Million USD | 100.17% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 216.099% |
| IXICO plc | -4.44 Million USD | 106.397% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 97.849% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.482% |
| CSL Limited | 10.52 Billion USD | 99.997% |
| Cellectis S.A. | -43.81 Million USD | 100.649% |